Assertion Supported AI assessment confidence: 90% certainty 4/5 debate potential 2/5

Bancel: Moderna trial data showed 90% of cancer antigens differ across patients

Stéphane Bancel · Inside Moderna’s Biggest mRNA Test Since COVID · Sep 2, 2026 · at 14:35

Moderna CEO Stéphane Bancel explains why shared-antigen cancer vaccines failed historically and why individualization is essential based on clinical data.

0:00 / 0:13exact quote · 13.3s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“And what we showed at ASCO and we published from a phase two study, but we believe it's the same thing in the phase three, because it's mechanistic, is that around 99 zero percent of the antigen are different patient to patient.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Moderna's Phase 2 clinical trial data published at ASCO showed that approximately 90% of tumor neoantigens differ from patient to patient.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Data from Moderna and Merck's Phase 2b trial (KEYNOTE-942 / mRNA-4157-P201) confirmed that tumor neoantigens are overwhelmingly patient-specific. In translational analyses of the Phase 2 cohort, 99.1% of identified neoantigens (3,401 out of 3,432) were completely unique to individual patients, with only 0.9% shared across patients due to recurrent hotspot mutations (such as BRAF and NRAS mutations). Whether the quote is interpreted as '90%' or '99.0%' ('99 zero percent'), the measured uniqueness (99.1%) directionally and substantially substantiates the claim.

KEYNOTE-942 translational analysis showed that 99.1% (3,401 neoantigens) of identified targets were unique to individual patients.
Only 0.9% of neoantigens were shared across multiple patients, driven by known melanoma hotspot mutations (e.g., BRAF V600E, NRAS Q61R).
Over 22.4% of patients had 100% unique neoantigens, and the remaining patients had a median uniqueness of 97.1%.

Checked against

[1] merck.com [2] asco.org [3] asco.org [4] nih.gov [5] europeanpharmaceuticalreview.com [6] ascopubs.org [7] publicnow.com [8] publicnow.com

"intismeran autogene" "neoantigens" "99.1%" OR "99%" OR "90%" mRNA-4157 KEYNOTE-942 neoantigens differ patient to patient Moderna Phase 2 ASCO neoantigens differ 90 percent mRNA-4157 "mRNA-4157" "neoantigen" "overlap" OR "unique" "percent" OR "%" "KEYNOTE-942" "neoantigens" "ASCO" "percent" OR "%" "Analysis of Individualized and Overlapping Neoantigens in Intismeran Autogene" mRNA-4157 neoantigens 90% ASCO

assessed as of 2026-09-02

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

ASCO cancer Moderna

⚑ Spot an error? Report it

More from Stéphane Bancel

Assertion Partly supported

Bancel: Moderna's mRNA shot is the first cancer vaccine that works

“Here it's the first time there is a cancer vaccine working. The field, as you know, has been doing that for 20 plus years. I think more than a thousand clinical trials that have all failed.”

Stéphane Bancel Sep 2, 2026 ▶ 3:31 Inside Moderna’s Biggest mRNA Test Since COVID

Assertion Supported

Bancel: Moderna's mRNA vaccine is first melanoma agent outperforming Keytruda alone

“It's the first time that there is an agent In melanoma that is better than Ketudra alone.”

Stéphane Bancel Sep 2, 2026 ▶ 3:22 Inside Moderna’s Biggest mRNA Test Since COVID

Assertion Supported

Bancel: Moderna and Merck Phase 3 individualized mRNA cancer trial is positive

“So indeed last week now we shared the news with our colleagues at Merck that after working 10 years on the individualized treatment against cancer using mRNA technology, that the phase three was positive.”

Stéphane Bancel Sep 2, 2026 ▶ 3:04 Inside Moderna’s Biggest mRNA Test Since COVID

Assertion Supported

Bancel: Moderna Phase 3 trial met primary and secondary endpoints at first interim analysis

“What we announced last week is that we met the primary End point of a study, which was recurrence-free survival, i.e. People having the cancer back or dying, that we met, and then to our own surprise, because this was the first interim analysis. This is not th…”

Stéphane Bancel Sep 2, 2026 ▶ 3:42 Inside Moderna’s Biggest mRNA Test Since COVID

Disclosure

Bancel: Moderna's Massachusetts factory is ready for individualized manufacturing at scale

“The factory is ready in Massachusetts, but we have figured out how to make and scale a product for every human being at the time.”

Stéphane Bancel Sep 2, 2026 ▶ 5:36 Inside Moderna’s Biggest mRNA Test Since COVID

Prediction Not checkable as stated

Bancel: Current cancer vaccine is the worst version medical history will ever see

“Well, it's exactly the same for Intismaran, which is the current version of Intismaran that Moderna is the worst version of Intismaran you're going to see for the rest of medical history.”

Stéphane Bancel Sep 2, 2026 ▶ 17:36 Inside Moderna’s Biggest mRNA Test Since COVID

Bancel: Moderna trial data showed 90% of cancer antigens differ across patients

More from Stéphane Bancel

Turn any episode into a week of clips.